Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables (2016 - 2020)

Viridian Therapeutics, Inc.\DE (VRDN) has 7 years of Notes Payables data on record, last reported at $4.7 million in Q3 2020.

  • For Q3 2020, Notes Payables fell 49.01% year-over-year to $4.7 million; the TTM value through Sep 2020 reached $4.7 million, down 49.01%, while the annual FY2019 figure was $4.0 million, 73.32% up from the prior year.
  • Notes Payables reached $4.7 million in Q3 2020 per VRDN's latest filing, up from $3.4 million in the prior quarter.
  • Across five years, Notes Payables topped out at $10.2 million in Q2 2019 and bottomed at $1.1 million in Q1 2016.
  • Average Notes Payables over 5 years is $4.7 million, with a median of $3.4 million recorded in 2020.
  • Peak YoY movement for Notes Payables: crashed 76.88% in 2018, then surged 615.03% in 2019.
  • A 5-year view of Notes Payables shows it stood at $4.8 million in 2016, then soared by 107.18% to $9.9 million in 2017, then plummeted by 76.88% to $2.3 million in 2018, then skyrocketed by 73.32% to $4.0 million in 2019, then grew by 18.39% to $4.7 million in 2020.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $4.7 million in Q3 2020, $3.4 million in Q2 2020, and $7.4 million in Q1 2020.